Higher concentrations of TKIs, such as pazopanib, are associated with improved outcomes in advanced RCC. A phase III trial failed to show disease-free survival benefit to pazopanib in the adjuvant setting, but improved DFS was seen in patients with higher Ctrough levels, supporting adequate drug exposure for optimal clinical outcome. Clin Cancer Res; 24(13); 2979–80. ©2018 AACR.
See related article by Sternberg et al., p. 3005
https://ift.tt/2lQBNgN
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου